Brind.

Apellis Pharmaceuticals reported that its revenue growth forecast is lower than the industry average.

1 report, 1 independent Updated Aug 2
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Apellis Pharmaceuticals reported that its revenue growth forecast is lower than the industry average.

Who's involved

What this event is mainly about

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • Simply Wall St.Apellis Pharmaceuticals Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag Revenue: US$178.5m (down 11% from 2Q 2024). Net loss: US$42.2m (loss widened by 12% from 2Q 2024). US$0.33 l